Key Takeaways:
Embecta Corp. shareholders face an Aug. 17 deadline to seek lead plaintiff status in a securities class action after the stock lost 57.8% in a single day.
"The company's guidance was misleading and unattainable, and defendants failed to disclose material adverse facts about the business," the complaint alleges.
The lawsuit covers investors who bought EMBC common stock between Nov. 25, 2025 and May 4, 2026. On May 5, Embecta reported second-quarter fiscal 2026 revenue that declined more than 14%, far worse than the flat-to-down-2% guidance it had issued. The company blamed weakness in its U.S. pen needle sales. Shares plunged $5.35 to close at $3.90.
The collapse erased more than half the company's market value in hours. Embecta had touted its pen needle business as "incredibly resolute" weeks before the miss, according to the complaint filed by Hagens Berman and other firms including Glancy Prongay and the Rosen Law Firm.
The lawsuit alleges Embecta knew or recklessly disregarded that its fiscal 2026 guidance was unattainable. The company lowered its full-year outlook alongside the second-quarter results, citing persistent weakness in the U.S. pen needle segment — a market facing competitive threats that the company had not disclosed, the complaint says.
Multiple law firms have announced investigations or filed similar complaints, including Bronstein, Gewirtz & Grossman and the Gross Law Firm. Investors who wish to serve as lead plaintiff must file motions by Aug. 17, 2026.
The 57.8% single-day decline ranks among the steepest for any U.S.-listed health-care company this year. Embecta, which was spun off from Becton Dickinson in 2022, derives the majority of its revenue from diabetes care products, including insulin pens and pen needles. The stock's decline puts it at its lowest since the spinoff, testing support levels not seen in the company's brief trading history. The next catalyst for shareholders is the Aug. 17 lead plaintiff deadline, after which the court will consolidate claims and schedule proceedings.
This article is for informational purposes only and does not constitute investment advice.
